# A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034

> **NCT01813812** · PHASE3 · UNKNOWN · sponsor: **Dong-A Pharmaceutical Co., Ltd.** · enrollment: 492 (estimated)

## Conditions studied

- Acute Gastritis
- Chronic Gastritis

## Interventions

- **DRUG:** DA-6034
- **DRUG:** Rebamipide 300mg

## Key facts

- **NCT ID:** NCT01813812
- **Lead sponsor:** Dong-A Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2013-08
- **Final completion:** —
- **Target enrollment:** 492 (ESTIMATED)
- **Last updated:** 2013-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813812, "A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01813812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*